© Cancer Research UK 2005 Registered charity number Hodgkin’s Lymphoma The statistics in this presentation are based on the Cervical CancerStats report published in However, the incidence, mortality and survival statistics have been updated to reflect the latest available data. For more information about UK cancer statistics please contact or visit

© Cancer Research UK 2005 Registered charity number Figure One: The lymphatic system showing sites commonly affected by Hodgkin's lymphoma

© Cancer Research UK 2005 Registered charity number Table One: Number of new cases and rates of Hodgkin's lymphoma, UK, 2006 EnglandWalesScotlandN.IrelandUK Cases Males Females Persons1, ,611 Crude rate per 100,000 population Males Females Persons Age-standardised rate (European) per 100,000 population Males % CI Females % CI Persons % CI

© Cancer Research UK 2005 Registered charity number Figure Two: Numbers of new cases and age specific incidence rates, by sex, Hodgkin's lymphoma, UK 2006

© Cancer Research UK 2005 Registered charity number Figure Three: Incidence of Nodular Sclerosis and Mixed Cellularity subtypes of Hodgkin's lymphoma by age and sex, England,

© Cancer Research UK 2005 Registered charity number Figure Four: Age-standardised* (European) incidence rates, Hodgkin's lymphoma, by sex, Great Britain, * to the European standard population

© Cancer Research UK 2005 Registered charity number Figure Five: Age-standardised* incidence and mortality rates for Hodgkin's lymphoma in males, selected EU countries, 2000 estimates * to the European standard population

© Cancer Research UK 2005 Registered charity number Figure Six: Proportion of EBV-associated Hodgkin's lymphoma cases by age group

© Cancer Research UK 2005 Registered charity number Table Two: Summary of Ann Arbor staging system Stage Description Stage I disease in single lymph node region Stage II disease in 2 or more regions on the same side of the diaphragm Stage III disease in lymph node regions on both sides of the diaphragm Stage IV diffuse or disseminated disease in one or more extralymphatic sites (e.g. liver and bone marrow) with or without lymph node involvement

© Cancer Research UK 2005 Registered charity number Table Three: Prognostic groups in early stage HD (EORTC) Group Prognostic factors very favourablestage I and age <40 and 'A' + ESR <50 + female and MT ratio* <0.35 favourable all other patients unfavourableage ≥50, or 'A' + ESR ≥50, or 'B' + ESR ≥30, or stage II 4/5 $, or MT ratio ≥0.35 *MT ratio = size of mediastinal mass compared with transverse diameter of chest on chest X-ray $ the subscript number denotes the number of nodal regions involved - an adverse prognostic factor ESR = erythrocyte sedimentation rate

© Cancer Research UK 2005 Registered charity number Table Four: Adverse prognostic factors in advanced HD according to the International Prognostic Factors Project Hb < 10.5g/l white cell count >16 x 109/l male gender lymphocytopenia <0.6 x 109/l or < 8% of total white cell count stage IV albumin <4g/l age 45 years

© Cancer Research UK 2005 Registered charity number Figure Seven: Tumour control rates according to number of risk factors from the International Prognostic Factors Project on Advanced Hodgkin's lymphoma

© Cancer Research UK 2005 Registered charity number Figure Eight: Age-standardised* relative survival by sex, for patients diagnosed with Hodgkin's lymphoma, England & Wales, to * to the European standard population

© Cancer Research UK 2005 Registered charity number Table Five: Numbers of deaths and rates of Hodgkin's lymphoma, UK by sex and country, 2003

© Cancer Research UK 2005 Registered charity number Figure Nine: Relative survival by sex and age group, for patients diagnosed with Hodgkin's lymphoma, England & Wales,

© Cancer Research UK 2005 Registered charity number Figure Ten: Number of deaths and age-specific mortality rates, Hodgkin's lymphoma, by sex, UK, 2007

© Cancer Research UK 2005 Registered charity number Figure Eleven: Age-standardised* (European) mortality, by sex, Hodgkin's lymphoma, United Kingdom, * to the European standard population